Recently, it has been shown that serum neurofilament light chain (NfL), a biomarker of axonal nerve damage, correlates with axonal loss from sural nerve biopsies, thus providing pathological evidence of the validity of NfL in quantifying axonal damage in peripheral neuropathies [3]. The gene discussed is NEFL; the disease is peripheral neuropathy.